Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
211results about How to "Reverse drug resistance" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Use of nano structured lipid carrier drug feeding system
InactiveCN101129335AIncrease intakeGood curative effectPowder deliveryOrganic active ingredientsLipid formationMonoglyceride
The invention discloses an application of nanometer structure lipid carrier administration system in the antineoplastic drug to reverse the multiple-drug tolerance of tumour cell, which comprises the following parts: solid lipid material, liquid lipid material and antineoplastic drug, wherein the rate of the liquid lipid (such as oleic acid) is 0-30wt%; the solid lipid is selected from monoglyceride; the liquid lipid is oleic acid; the antineoplastic drug is Paclitaxel or adriablastina. The invention has highly effective cell uptaking and cytolymph condensing function with packing molecular target in the antineoplastic drug of cell, which avoids P-glucoprotein in the drug tolerant cytolymph from identifying the antineoplastic drug to reduce exclusion.
Owner:ZHEJIANG UNIV
Pharmaceutical composition and application thereof in preparing medicine for treating multidrug resistance of tumors
ActiveCN108159038AGood reversal of drug resistanceAvoid drug resistanceOrganic active ingredientsImmunoglobulinsPD-L1 inhibitorChlorogenic acid
The invention discloses a pharmaceutical composition and an application thereof in preparing a medicine for treating multidrug resistance of tumors and belongs to the field of biomedicines. The pharmaceutical composition is prepared from chlorogenic acid and tonka-bean quinic acid and can be used for preparing a reversal agent and a PD-1 / PD-L1 inhibitor for the multidrug resistance of the tumors.The pharmaceutical composition and the application disclosed by the invention have the beneficial effects that by combined use of the chlorogenic acid and the tonka-bean quinic acid, the synergistic interaction can be exerted, the drug-resistance reversal action on the tumor cell strain generating multidrug resistance for chemotherapeutic drugs and immunotherapeutic drugs is good, the expression of PD-1 / PD-L1 of tissues of transplanted tumors of mice with drug-resistant B16 melanoma and drug-resistant Lewis lung cancer can be effectively suppressed, and a role in proliferating CD4+T and CD8+Tcells of the mice with the drug-resistant B16 melanoma and the drug-resistant Lewis lung cancer can be effectively played.
Owner:SICHUAN JIUZHANG BIO TECH CO LTD
Tumor-targeted sound and light power medicine-carrying nanometer nano-micelle, and preparation method and purpose thereof
InactiveCN106551904AHigh drug loadingControlled and orderly releaseOrganic active ingredientsEnergy modified materialsTumor targetPolyethylene glycol
The invention relates to a tumor-targeted sound and light power medicine-carrying nanometer nano-micelle, and a preparation method and a purpose thereof. The medicine-carrying nanometer nano-micelle is structurally characterized in that porphyrins compounds and anthracyclines chemotherapeutic medicine form a nanometer composition through a pi-pi conjugation effect; and amphiphilic block copolymers with PEO (polyoxyethylene) or PEG (polyethylene glycol) hydrophilic segments cover nanometer compounds through the hydrophobic effect to form a hydrophilic case. The medicine-carrying nanometer nano-micelle is in a regular spherical form, and has the advantages of uniform distribution, stable property and high medicine carrying capacity; the medicine can be conveyed to the tumor focus in the targeted way and can be effectively enriched in the tumor tissue; under the ultrasound (illumination) condition, the treatment effect of the anthracyclines chemotherapeutic medicine on the tumor can be obviously enhanced; and the tumor drug resistance can be effectively reversed. Wide clinic application prospects can be realized in an aspect of combined tumor treatment by a sound (light) power therapy method and chemotherapy.
Owner:TIANJIN MEDICAL UNIV
Holly bark containing compound composition for treating escherichia coli infected diseases of livestock and poultry
ActiveCN103127507AReverse drug resistanceGood treatment effectAntibacterial agentsPlant ingredientsEscherichia coliDisease
The invention relates to a holly bark containing compound composition for treating escherichia coli infected diseases of livestock and poultry. The compound composition is prepared from the following raw materials in parts by weight: 3 to 30 parts of antibacterial drug, and 5 to 200 parts of holly bark. The raw materials are uniformly mixed to prepare powder, tablets, oral liquid or granules which are added into animal feed in a ratio of 0.1 to 5g / kg feed addition amount for feeding, and the drug resistances of bacteria to the antibacterial drug can be reversed, so that the treatment effect of antibacterial drugs can be improved, the administration cost can be greatly reduced, and higher economic benefit can be created for farmers.
Owner:XUZHOU TIANYI ANIMAL PHARMA
Anti-tumor combined medicament
InactiveCN102697795AReverse drug resistanceLow toxicityPowder deliveryOrganic active ingredientsEntrapmentQuercetin
The invention discloses applications of pharmorubicin and quercetin to preparation of an anti-tumor combined medicament. The invention further discloses a combined medicament. The pharmorubicin is taken as an anti-tumor medicament; the quercetin is taken as an MDR (Multiple Drug Resistance) reversal agent of the pharmorubicin; PLGA (Poly(Lactic-Co-Glycolic Acid)) is taken as nanoparticle copolymer material; compound nanoparticles of pharmorubicin and quercetin are entrapped during preparation, so that a certain entrapment efficiency and medicament loading amount are achieved; various indexes of the nanoparticles are used for evaluating the property of the medicament; and an in-vitro cell test is used for evaluating the reversed multi-medicament resistance effect of the medicament. EPI-QC (Epichlorohydrin-QC) compound nanoparticles are prepared by adopting an emulsified solvent evaporation method; and according to research on a comparison system, the EPI-QC compound nanoparticles can be used for reverting the medicament tolerance of tumor cells in a certain degree, and the toxicity on normal cells is lowered.
Owner:CHENGDU MEDICAL COLLEGE
Gene and drug co-transported PLGA ultrasonic nano bubbles as well as preparation method and application thereof
InactiveCN104225633ALong-term cryopreservationLong storage timeOrganic active ingredientsPowder deliveryUltrasound imagingMedicine
The invention relates to PLGA ultrasonic nano bubbles integrating ultrasonic imaging, drug delivery and gene therapy into a whole and a preparation method thereof. The preparation method comprises the following steps: preparing drug-loading nano bubbles loaded with a chemotherapy drug DOX, further modifying PLGA nano bubbles through PEI, adsorbing shRNA plasmids of MDR-1, thereby forming the composite nano bubbles. The nano bubbles have high drug loading rate and encapsulation efficiency, drug release has pH responsiveness, the loaded genes can be protected, expression of drug resistance genes MDR-1 is effectively silenced, the ultrasonic imaging capacity can be exerted, and the drugs and genes can be simultaneously and efficiently delivered to tumor locations to exert a synergistic effect.
Owner:UNIV OF ELECTRONICS SCI & TECH OF CHINA
Application of polymer based on beta-cyclodextrin
ActiveCN101766821AReverse drug resistanceGood biocompatibilityOrganic active ingredientsPharmaceutical delivery mechanismPolymer scienceBiocompatibility Testing
The invention provides the application of a polymer system based on beta-cyclodextrin in P-glycoprotein of suppressive tumour cells. The polymer consists of the beta-cyclodextrin and grafted amphipathy polymer. The star-shaped amphipathy polymer based on beta-CD and provided by the invention has remarkable effect of restraining P-gp protein, and the restraining effect thereof is obviously superior to the inhibitor CsA of the P-gp protein. The polymer of the invention has the characteristics of low cytotoxicity, good biocompatibility, biodegradability, long intracorporeal circulation time and the like, and provides an ideal dose carrier material for hydrophobic antineoplastic agents.
Owner:ZHEJIANG UNIV
Acalypha australis L. and beta-lactam antibacterial medicine containing compound medicine for livestock and poultry
ActiveCN103989728AReverse drug resistanceGood treatment effectAntibacterial agentsHeterocyclic compound active ingredientsAcalypha australisBeta-lactam
Owner:GUANGXI UNIV
Methotrexate (MTX)-Pluronic copolymer mixed micelle carrying indissoluble medicament and preparation method thereof
InactiveCN103006535AHigh drug loadingReverse drug resistanceOrganic active ingredientsPharmaceutical delivery mechanismChemical ligationMixed micelle
The invention belongs to the technical field of biological medicine and relates to a novel methotrexate (MTX)-Pluronic copolymer mixed micelle carrying an indissoluble medicament and a preparation method thereof. The method comprises the following steps of: performing chemical connection and copolymerization on Pluronic and MTX to obtain an MTX-Pluronic copolymer; and mixing the MTX-Pluronic copolymer with Pluronic-kind matters to prepare an MTX-Pluronic copolymer mixed micelle system, wherein a hydrophobic core of the mixed micelle carries the indissoluble medicament. Tests prove that the mixed micelle can improve the medicament-loading capacity of the indissoluble medicament, effectively reverses the medicament tolerance of tumors and has the medicament-delivery characteristic targeting folate receptors.
Owner:FUDAN UNIV
Adriamycin nano drug delivery system as well as preparation method and application thereof
ActiveCN103976950AUniform particle sizeLarge particle sizeOrganic active ingredientsOrganic non-active ingredientsLipid formationOrganic solvent
The invention discloses an adriamycin nano drug delivery system as well as a preparation method and application thereof. The drug delivery system comprises the following components in percentage by weight: 0.02%-1.5% of active ingredient containing adriamycin, 1%-20% of solid lipid, 0.1%-20% of liquid lipid, 0.5%-20% of emulsifier and 0.1%-5% of isoosmotic adjusting agent, wherein the solid lipid and the liquid lipid form nanoparticles to cover the active ingredient containing the adriamycin. The preparation method comprises the following steps: (1), uniformly dispersing the active ingredient containing the adriamycin, the solid lipid, the liquid lipid and fat-soluble emulsifier in an organic solvent, evaporating the organic solvent to obtain an oil phase; (2), uniformly dispersing other emulsifiers and the isoosmotic adjusting agent in water to obtain a water phase; (3), adding the water phase into the oil phase for emulsifying drop by drop; (4), homogenizing under high pressure; (5), cooling and degerming. The adriamycin nano drug delivery system disclosed by the invention can be used for realizing co-transporting of the adriamycin and a chemosensitizer, so that the killability of the adriamycin on liver cancer cells is strengthened.
Owner:HUAZHONG UNIV OF SCI & TECH +1
Anticancer tumour extinguishing toxin expelling decoction
Disclosed is an anticancer tumour extinguishing toxin expelling decoction, which is prepared from Chinese medicinal herbs including toad, Eupolyphaga Sinensis Walker, leeches, cantharis, house lizard, astragalus root, gen-seng, ganoderma lucidum, notoginseng, white atractylodes rhizome, burred tuber, zedoary, peach kernels, safflower and Oldenlandis.
Owner:钟伟
A pegylated and fatty acid grafted chitosan oligosaccharide, synthesis method and application for drug delivery system
ActiveUS20110118200A1Promote absorptionStable maintenanceBiocideGenetic material ingredientsSynthesis methodsFatty acid
The present invention provides a PEGylated and fatty acid grafted chitosan oligosaccharide comprising a structural unit represented by the following Formula (I) and a structural unit represented by the following Formula (II) and synthesize method, wherein the chitosan oligosaccharide has a molecular weight of less than 200,000 Da, and a degree of deacetylation of 70%-100%, and part of free amino groups of chitosan oligosaccharide chain are replaced by a fatty acid or PEG, where n refers to degree of polymerization of the PEG, and R is an alkyl group having 11-21 carbon atoms. The grafting ratio of fatty acids is 1%-50%, and the grafting ratio of PEG is 0.05%-50%. The present invention also comprise a pharmaceutical composition comprising the PEGylated and fatty acid grafted chitosan oligosaccharide as a carrier, and use of the PEGylated and fatty acid grafted chitosan oligosaccharide in preparation of a pharmaceutical composition.
Owner:ZHEJIANG UNIV
Herba lycopi containing compound composition for treating escherichia coli infected diseases of livestock and poultry
ActiveCN103127508AReverse drug resistanceGood treatment effectAntibacterial agentsHeterocyclic compound active ingredientsDiseaseEscherichia coli
The invention relates to a herba lycopi containing compound composition for treating escherichia coli infected diseases of livestock and poultry. The compound composition is prepared from the following raw materials in parts by weight: 3 to 30 parts of antibacterial drugs, and 5 to 200 parts of herba lycopi. The raw materials are uniformly mixed to prepare powder, tablets, oral liquid or granules which are added into animal feed in a ratio of 0.1 to 5g / kg feed addition amount for feeding, and the drug resistances of bacteria to the antibacterial drug can be reversed, so that the treatment effect of antibacterial drugs can be improved, the administration cost can be greatly reduced, and higher economic benefit can be created for farmers.
Owner:XUZHOU TIANYI ANIMAL PHARMA
Acalypha australis L. and amikacin containing compound medicine for livestock and poultry
InactiveCN103989725AReverse drug resistanceGood treatment effectAntibacterial agentsOrganic active ingredientsBacteroidesTreatment effect
Owner:GUANGXI UNIV
Creat/amikacin-containing compound medicine for livestock and fowl
InactiveCN103933086AReverse drug resistanceGood treatment effectAntibacterial agentsOrganic active ingredientsTreatment effectAntibacterial agent
Owner:GUANGXI UNIV
Nanoparticle liposome for releasing different medicines in programmed manner and preparation and use thereof
InactiveCN102188439AIncrease profitReverse drug resistanceOrganic active ingredientsPharmaceutical non-active ingredientsCholesterolDidodecyldimethylammonium bromide
The invention discloses a nanoparticle liposome for releasing different medicines in programmed manner and preparation and use thereof. The nanoparticle liposome is mainly prepared from the following components in part by mass: 19.34 to 50.79 parts of polylactic-co-glycolic acid, 5.78to 25.73 parts of dihydroartemisinin and phospholipid composite, 0.01 to 25.27 parts of phospholipid, 0.01 to 15.38 parts of didodecyldimethylammonium bromide, 0.01 to 20.0 parts of cholesterol, and 0.01 to 10.16 parts of adriamycin, wherein the molecular weight of the polylactic-co-glycolic acid is 5,000 to 300,000, and the phospholipid is natural phospholipid or synthetic phospholipid. The nanoparticle liposome for loading medicines of different natures can be used for treating breast cancer and leukocythemia, which have resistance to adriamycin, inverse the medicine resistance of tumors, improve the utilization rate of medicines and reduce pain in patients and the medical cost of patients.
Owner:ZHEJIANG UNIV
Antineoplastic combined drug, and applications thereof in preparation of anticancer drugs
InactiveCN107441075AReverse drug resistanceSymptoms improvedOrganic active ingredientsAntibody ingredientsSide effectChlorogenic acid
The invention discloses an antineoplastic combined drug, and applications thereof in preparation of anticancer drugs. The antineoplastic combined drug comprises, by weight, 10 to 40 parts of a first reagent and 2 to 40 parts of a second reagent. The invention also discloses applications of chlorogenic acid in preparing anticancer drug toxic and side effect inhibitors. EGFR is taken as the target point of the anticancer drugs. According to the applications, the targeting performance of the anticancer drugs in treatment of non-small cell carcinoma, breast cancer, malignant gliomas, and nasopharyngeal carcinoma is improved, the toxic and side effect is reduced, and generation resistance on the drugs taking EGFR as the target point is delayed.
Owner:SICHUAN JIUZHANG BIO TECH CO LTD
Compound medicine comprising herba lycopi and florfenicol and used for livestock and poultry
InactiveCN103961400AReverse drug resistanceGood treatment effectAntibacterial agentsOrganic active ingredientsEconomic benefitsTherapeutic effect
The invention relates to a compound medicine comprising herba lycopi and florfenicol and used for livestock and poultry. The compound medicine comprises the following raw materials in parts by weight: 3 to 20 parts of florfenicol and 10 to 180 parts of herba lycopi. The raw materials are uniformly mixed to be prepared into powder, tablets, an oral liquid or granules to be added into livestock and poultry feed according to the additive amount of 0.1-5 g / kg for feeding, and drug resistance of antibacterial on bacteria can be reversed, so that the treatment effect of the antibacterial can be improved, the medicine cost can be greatly reduced, and higher economic benefits are created for farmers.
Owner:GUANGXI UNIV
Acalypha australis L. and mequindox containing compound medicine for livestock and poultry
InactiveCN103989727AReverse drug resistanceGood treatment effectAntibacterial agentsOrganic active ingredientsLivestockAnimal science
Owner:GUANGXI UNIV
Acalypha australis L. and sulfamonomethoxine sodium containing compound medicine for livestock and poultry
InactiveCN103989729AReverse drug resistanceGood treatment effectAntibacterial agentsOrganic active ingredientsBacteroidesTreatment effect
Owner:GUANGXI UNIV
Acalypha australis L. and fosfomycin containing compound medicine for livestock and poultry
InactiveCN103989726AReverse drug resistanceGood treatment effectAntibacterial agentsOrganic active ingredientsBacteroidesTreatment effect
Owner:GUANGXI UNIV
Medicine composition for reversing cancer cell tolerance and application of medicine composition
ActiveCN102631345AGrowth inhibitionReduce the ratioOrganic active ingredientsAntineoplastic agentsCancer cellTraditional medicine
The invention relates to a medicine composition for reversing cancel cell tolerance and application of the medicine composition, and particularly discloses an isocorydin (ICD) and a pharmaceutically acceptable novel use of salt of the isocorydin (ICD), which are used for preparing the medicine composition for treating cancer. The medicine composition can increase sensitivity of cancer cells to anti-cancer medicines, or reduce cancel cell tolerance to the anti-cancer medicines.
Owner:SHANGHAI INST OF ONCOLOGY
Tumor-targeting nano-composite Apt-PAMAM/ERL/SUV and preparation and application thereof
InactiveCN107998083AGood water solubilityImprove targetingPowder deliveryOrganic active ingredientsSolubilityTumor target
The invention discloses a preparation method of tumor-targeting aptamer-modified drug gene co-transport nanoparticles and application of the nanoparticles in preparation of EGFR-mutation-resistant drugs for lung cancer. The preparation method comprises the specific steps that firstly, Apt carboxyl is activated first and then reacted with amino on the surface of PAMAM, an Apt-PAMAM carrier is synthesized, the drug ERL is encapsulated to form an Apt-PAMAM / ERL nano-drug, and the Apt-PAMAM / ERL nano-drug is compounded with SUV to form a tumor-targeting nano-composite. By means of the composite, thedefect that the ERL is poor in water solubility is overcome, and meanwhile, the surface-modified Apt and ERL dual-targeting EGFR mutation tumor cells are utilized so as to increase targeting of tumortissue; through compounding with the SUV, expression of anti-apoptosis genes is silenced, the drug resistance of the cells to the ERL is reversed, therefore, the bioavailability of the drug is effectively improved, and the clinical application value of the drug is improved.
Owner:FUZHOU UNIV
Anti-tumor combined drug and use thereof in preparing anti-cancer drug
ActiveCN107375258AReverse drug resistanceAntineoplastic agentsHeterocyclic compound active ingredientsKidney cancerChlorogenic acid
The invention discloses an anti-tumor combined drug and use thereof in preparing an anti-cancer drug. The combined drug comprises 10-40 weight parts of a first preparation and 2-100 weight parts of a second preparation. The invention further discloses use of chlorogenic acid in preparing an anti-cancer drug toxic and side effect inhibitor, and the anti-cancer drug is a VEGF channel inhibitor. According to the technical scheme adopted by the invention, targeting ability, to lung cancer and kidney cancer, of the VEGF channel inhibitor can be improved, and the toxic and side effect of the VEGF channel inhibitor can be reduced; and moreover, drug resistance of a VEGF tyrosine kinase inhibitor further can be reversed.
Owner:SICHUAN JIUZHANG BIO TECH CO LTD
Anti-CA (candida albicans) product combining harmine hydrochloride and fluconazole and application of product
InactiveCN107519167AHigh antibacterial activityReverse drug resistanceOrganic active ingredientsAntimycoticsHarmineMinimum inhibitory concentration
The invention discloses an anti-CA (candida albicans) product combining harmine hydrochloride and fluconazole and an application of the product and belongs to the technical field of medicines. The combined antifungal function of fluconazole and harmine hydrochloride on drug-resistant CA are researched with multiple methods. The effective concentration of fluconazole to harmine hydrochloride is 1:32 (mu g / mL, for CA3) or 1:16 (mu g / mL, for CA2) when fluconazole and harmine hydrochloride are combined to be applied, the minimum inhibitory concentration is 8 mu g / mL and 0.25 mu g / mL (for CA3) or 0.5 mu g / mL (for CA4). When harmine hydrochloride and fluconazole are combined, the antibacterial activity of fluconazole for drug-resistant CA can be enhanced, the coordinated antifungal action can be generated, the drug resistance of drug-resistant CA to fluconazole can be reversed, and a research direction is provided for development of new drugs and new application of old drugs.
Owner:QILU CHILDRENS HOSPITAL OF SHANDONG UNIV
Combined drug used for treating cancers
ActiveCN107441076AReverse drug resistanceOvercome toxic side effectsOrganic active ingredientsPeptide/protein ingredientsSide effectChlorogenic acid
The invention discloses a combined drug used for treating cancers. The combined drug contains chlorogenic acid and hormone drugs of the same or different unit dosages used for simultaneous or respective using, and pharmaceutically acceptable carriers. According to the combined drug, chlorogenic acid and hormone drugs are used together, so that synergistic interaction is achieved, defects of single drug treatment that toxic and side effect is obvious or curative effect is poor are avoided; the combined drug is excellent in curative effect, low in toxicity, is capable of reversing drug resistance on hormone drugs, and is promising in clinical application prospect.
Owner:SICHUAN JIUZHANG BIO TECH CO LTD
Red paeonia/amikacin-containing compound medicine for livestock and fowl
ActiveCN103948692AReverse drug resistanceGood treatment effectAntibacterial agentsOrganic active ingredientsBacteroidesTreatment effect
Owner:广西南宁市桃源兽药厂
Long-chain non-coding RNA PRALR, and expression plasmid and use thereof
PendingCN110129318AReverse drug resistanceOutstanding reversal effectOrganic active ingredientsGenetically modified cellsDrugChemotherapeutic drugs
The invention relates to a long-chain non-coding RNA PRALR, and an expression plasmid and a use thereof. Starting from TCONS-00013523 sequence, a complete gene sequence is discovered by 5'-RACE and 3'-RACE technologies and is named as PRALR (paclitaxel resistance-associated lncRNA, paclitaxel resistance-associated long-chain non-coding RNA). Then, the PRALR expression plasmid and siRNA are constructed, and the PRALR is further confirmed to be a novel ovarian cancer drug resistance-associated lncRNA; the constructed PRALR expression plasmid can significantly increase the expression quantity ofthe PRALR, and the designed siRNA can significantly reverse drug resistance of paclitaxel-resistant ovarian carcinoma cells. A powerful tool is provided for study of the mechanism of paclitaxel resistance and other chemotherapeutic drug resistance, and a reference is provided for clinical development of drugs to reverse the drug resistance of tumor to paclitaxel.
Owner:JINSHAN HOSPITAL FUDAN UNIV
Compound medicine containing radix paeoniae rubrathe and fluoroquinolones antibacterial drug used for livestock and poultry
ActiveCN103977088AReverse drug resistanceGood treatment effectAntibacterial agentsOrganic active ingredientsParticulatesTreatment effect
Owner:GUANGXI UNIV
Antifungal product combining ambroxol hydrochloride with fluconazole and application thereof
ActiveCN105663126AHigh antibacterial activityReverse drug resistanceOrganic active ingredientsAntimycoticsCombined useFluconazole
The invention discloses an antifungal product combining ambroxol hydrochloride with fluconazole and application thereof and belongs to the technical field of medicine. Static and dynamic combined antifungal effect, on medicine-resistant Candida albicans, of combined use of fluconazole and ambroxol hydrochloride is studied through various methods. An effective concentration proportion of fluconazole to ambroxol hydrochloride when ambroxol hydrochloride and fluconazole are combined for application is 1:64 (ug / mL), and lowest antibacterial concentrations are 128 ug / mL and 2 ug / mL respectively. When ambroxol hydrochloride is combined with fluconazole, antibacterial activity, to medicine-resistant Candida albicans, of fluconazole can be improved, synergistic antifungal effect can be generated, medicine resistance, to fluconazole, of medicine-resistant Candida albicans can be reversed, and a studying direction is provided for development of new drugs and new application of old drugs.
Owner:QIANFOSHAN HOSPITAL OF SHANDONG
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com